Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Retained Earnings (2024 - 2025)

Historic Retained Earnings for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$666.6 million.

  • Prelude Therapeutics' Retained Earnings fell 2014.52% to -$666.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$666.6 million, marking a year-over-year decrease of 2014.52%. This contributed to the annual value of -$583.6 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Prelude Therapeutics' Retained Earnings stood at -$666.6 million, which was down 2014.52% from -$646.9 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Retained Earnings ranged from a high of -$487.8 million in Q1 2024 and a low of -$666.6 million during Q3 2025